Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation RegistryRoel J.W. van Kampen, Anna Sureda, Carmen Canals et al.|Journal of Clinical Oncology|2011Cited by 216
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>Mark J. Levis, Yves Béguin, Masumi Ueda et al.|Journal of Clinical Oncology|2024Cited by 204
Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long‐term outcomesKarl S. Peggs, Anna Sureda, Wendi Qian et al.|British Journal of Haematology|2007Cited by 106
Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working PartyAlina Tănase, Norbert Schmitz, Harald Stein et al.|Leukemia|2014Cited by 73
Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT)Esa Jantunen, Anna Sureda, Michel Attal et al.|Annals of Oncology|2011Cited by 58